Literature DB >> 20034098

Diagnostic utility of daytime salivary melatonin levels in Smith-Magenis syndrome.

Constance L Chik1, Mark D Rollag, Wallace C Duncan, Ann C M Smith.   

Abstract

An inverted circadian rhythm of melatonin (MT) likely contributes to the sleep disturbance in patients with Smith-Magenis syndrome (SMS). Plasma MT levels have documented this altered rhythm, but daytime levels of salivary MT has not been determined. Daytime measures of salivary MT might have utility in home/outpatient settings for assessing MT levels in undiagnosed patients with clinical features of SMS. The objective of this study was to determine the utility of daytime salivary MT as a diagnostic test in SMS. Thirty individuals with confirmed SMS [28 with del 17p11.2 and 2 with the retinoic acid induced 1 (RAI1) gene mutation] and five controls were studied. Single or serial daytime salivary MT levels were measured. The mean midday salivary MT level was 79.0 pg/ml in SMS patients, compared with 16.3 pg/ml in controls, with nine patients having values similar to controls. The median MT level in SMS patients was 49.0 pg/ml (first and third quartile values = 15.5 and 106.8 pg/ml). Twenty-six (90%) of 29 patients had at least one MT value >15.5 pg/ml, including 70 (78%) of 90 samples from patients with del 17p11.2 and one (20%) of five samples from the two patients with the RAI1 mutation. Neither the pattern of medication use nor age had an effect on daytime salivary MT levels. Although most SMS patients had elevated daytime salivary MT levels, multiple sampling appears necessary to distinguish patients with SMS from other conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20034098      PMCID: PMC2802065          DOI: 10.1002/ajmg.a.33158

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  30 in total

1.  Point and interval estimations of circadian melatonin ecphasia in Smith-Magenis syndrome.

Authors:  Germaine Cornélissen; Franz Halberg; Roberto Tarquini; Federico Perfetto; Roberto Salti; Giacomo Laffi; Kuniaki Otsuka
Journal:  Biomed Pharmacother       Date:  2003-10       Impact factor: 6.529

2.  Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome.

Authors:  H De Leersnyder; M C De Blois; B Claustrat; S Romana; U Albrecht; J C Von Kleist-Retzow; B Delobel; G Viot; S Lyonnet; M Vekemans; A Munnich
Journal:  J Pediatr       Date:  2001-07       Impact factor: 4.406

3.  Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.

Authors:  L Potocki; D Glaze; D X Tan; S S Park; C D Kashork; L G Shaffer; R J Reiter; J R Lupski
Journal:  J Med Genet       Date:  2000-06       Impact factor: 6.318

4.  Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor.

Authors:  G C Brainard; J P Hanifin; J M Greeson; B Byrne; G Glickman; E Gerner; M D Rollag
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

5.  beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome.

Authors:  H De Leersnyder; M C de Blois; M Vekemans; D Sidi; E Villain; C Kindermans; A Munnich
Journal:  J Med Genet       Date:  2001-09       Impact factor: 6.318

6.  Melatonin treatment for age-related insomnia.

Authors:  I V Zhdanova; R J Wurtman; M M Regan; J A Taylor; J P Shi; O U Leclair
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

Review 7.  Melatonin: clinical relevance.

Authors:  Russel J Reiter
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2003-06       Impact factor: 4.690

8.  Review of disrupted sleep patterns in Smith-Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion.

Authors:  Eilis A Boudreau; Kyle P Johnson; Angela R Jackman; Jan Blancato; Marjan Huizing; Claude Bendavid; Marypat Jones; Settara C Chandrasekharappa; Alfred J Lewy; Ann C M Smith; R Ellen Magenis
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

9.  Mutations in RAI1 associated with Smith-Magenis syndrome.

Authors:  Rebecca E Slager; Tiffany Lynn Newton; Christopher N Vlangos; Brenda Finucane; Sarah H Elsea
Journal:  Nat Genet       Date:  2003-03-24       Impact factor: 38.330

10.  Exercise elicits phase shifts and acute alterations of melatonin that vary with circadian phase.

Authors:  Orfeu M Buxton; Calvin W Lee; Mireille L'Hermite-Baleriaux; Fred W Turek; Eve Van Cauter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-03       Impact factor: 3.619

View more
  3 in total

1.  De Novo KAT5 Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy.

Authors:  Jonathan Humbert; Smrithi Salian; Periklis Makrythanasis; Gabrielle Lemire; Justine Rousseau; Sophie Ehresmann; Thomas Garcia; Rami Alasiri; Armand Bottani; Sylviane Hanquinet; Erin Beaver; Jennifer Heeley; Ann C M Smith; Seth I Berger; Stylianos E Antonarakis; Xiang-Jiao Yang; Jacques Côté; Philippe M Campeau
Journal:  Am J Hum Genet       Date:  2020-08-20       Impact factor: 11.025

2.  Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith-Magenis syndrome, a neurodevelopmental disorder.

Authors:  Ann C M Smith; Rebecca S Morse; Wendy Introne; Wallace C Duncan
Journal:  Am J Med Genet A       Date:  2019-02       Impact factor: 2.802

Review 3.  Congenital scoliosis in Smith-Magenis syndrome: a case report and review of the literature.

Authors:  Zheng Li; Jianxiong Shen; Jinqian Liang; Lin Sheng
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.